Every compliance officer knows that third parties bring risk to the business. Few compliance officers, however, face as much third-party risk as those working in life sciences, medical devices, and healthcare.

Increased globalization has resulted in life sciences companies increasing the use of third parties for many aspects of their businesses, from research to manufacturing to distribution –  magnifying the corruption risk posed by vendors and partners. Coupled with the announcement in July by the U.S. Department of Justice of a new partnership between its Healthcare Fraud Unit and its FCPA Unit, to probe healthcare companies that “might be bribing foreign governments”, life sciences companies are taking even greater steps to ensure these risks are mitigated effectively.

So, what are these heightened risks, exactly? Where do they come from? And how can compliance officers design an effective way to assess those third-party risks?

Download “Identifying Third-Party Risks in the Life Science Sectors”, to learn more.